Shareholder Tools
Investor Relations Contacts
Sarah CavanaughVice President
Investor Relations & Corporate Communications
Email Investor RelationsMore »
Investor Relations
Celldex Therapeutics, Inc. is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
View all » 
Recent Releases
May 6, 2013
Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 Antibody Day
May 2, 2013
Celldex Reports First Quarter 2013 Financial Results
What's New
More »Featured Events
|
|
Celldex Therapeutics, Inc. to Discuss Topline Results of Phase 2b EMERGE Study of CDX-011 Conference Call |
|
|
Celldex Therapeutics, Inc. Research and Development Day |
More »Upcoming Events
| Details on upcoming events are not yet available. |
Featured Financial Reports
| Filing Date | Title | Type | Size | |
|---|---|---|---|---|
| May 3, 2013 | 10-Q |
|
659.8 KB | |
| Oct 11, 2011 | 2011 Form 10-K |
|
513.9 KB | |
